Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Forterra statutory pre-tax profits grow in FY24 despite 'challenging market conditons'

(Sharecast News) - Building products manufacturer Forterra said on Wednesday that pre-tax profits had grown in FY24 despite ongoing "challenging market conditions". Forterra said revenues had slipped 0.6% to £344.3m and adjusted EBITDA margins contracted 170 basis points to 15.1%.

However, statutory underlying earnings rose 24% to £54.7m and statutory pre-tax profits surged 45.0% to £24.8m. Statutory earnings per share rose 33.9% to 8.3p.

Forterra stated UK brick despatches were up 2% year-on-year, with Q4 despatches roughly 20% higher. However, total UK brick consumption was approximately 30% behind the level seen in 2022.

Chief executive Neil Ash said: "2024 saw the continuation of the challenging market conditions we have witnessed over the last two years, though the second half saw an improving position. Our focus has been on the areas we can control and delivered a resilient performance by successfully aligning our production to demand and returning the group to a position of strong cash generation.

"During 2025, we anticipate some recovery in our markets, whilst remaining mindful of the wider macroeconomic conditions. Following our significant strategic investment in increased manufacturing capacity, the group remains well placed as its key markets recover."

As of 0930 GMT, Forterra shares were up 4.28% at 165.80p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.